Clinical Trials
15 trialsNCT06045585 2023-09-21
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
Guangdong Second Provincial General Hospital
Phase EARLY_PHASE1 Unknown
NCT05673447 2023-08-28
The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
Changhai Hospital
Phase EARLY_PHASE1 Unknown
NCT05105867 2023-05-10
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Unknown
NCT05739227 2023-02-22
Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies
Xuzhou Medical University
Phase EARLY_PHASE1 Unknown
NCT04412174 2020-06-02
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
Hebei Yanda Ludaopei Hospital
Phase EARLY_PHASE1 Unknown
NCT04264039 2020-02-11
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT04191941 2019-12-10
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Timmune Biotech Inc.
Phase EARLY_PHASE1 Unknown
NCT04169932 2019-11-20
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
Shanghai Longyao Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04156178 2019-11-12
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT04156243 2019-11-12
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT04028440 2019-09-26
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Unknown
NCT03690310 2019-01-31
Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03824951 2019-01-31
Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03824964 2019-01-31
Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03692767 2019-01-30
Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown